141 related articles for article (PubMed ID: 33614241)
1. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer.
Gorur A; Bayraktar R; Ivan C; Mokhlis HA; Bayraktar E; Kahraman N; Karakas D; Karamil S; Kabil NN; Kanlikilicer P; Aslan B; Tamer L; Wang Z; Cristini V; Lopez-Berestein G; Calin G; Ozpolat B
Mol Ther Nucleic Acids; 2021 Mar; 23():930-943. PubMed ID: 33614241
[TBL] [Abstract][Full Text] [Related]
2. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
[No Abstract] [Full Text] [Related]
3. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway.
Wang X; Chen T; Zhang Y; Zhang N; Li C; Li Y; Liu Y; Zhang H; Zhao W; Chen B; Wang L; Yang Q
J Cell Physiol; 2019 Aug; 234(8):13303-13317. PubMed ID: 30618083
[TBL] [Abstract][Full Text] [Related]
7. miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells.
Li D; Hu J; Song H; Xu H; Wu C; Zhao B; Xie D; Wu T; Zhao J; Fang L
Am J Transl Res; 2017; 9(5):2276-2285. PubMed ID: 28559978
[TBL] [Abstract][Full Text] [Related]
8. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.
Chen H; Pan H; Qian Y; Zhou W; Liu X
Mol Cancer; 2018 Jan; 17(1):4. PubMed ID: 29310680
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-301a-3p promotes triple-negative breast cancer progression through downregulating MEOX2.
Liu H; Wang G
Exp Ther Med; 2021 Sep; 22(3):945. PubMed ID: 34306209
[TBL] [Abstract][Full Text] [Related]
10. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene.
Menbari MN; Rahimi K; Ahmadi A; Mohammadi-Yeganeh S; Elyasi A; Darvishi N; Hosseini V; Abdi M
J Cell Physiol; 2020 Mar; 235(3):2631-2642. PubMed ID: 31508813
[TBL] [Abstract][Full Text] [Related]
11. miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2.
Jia Z; Liu Y; Gao Q; Han Y; Zhang G; Xu S; Cheng K; Zou W
Gene; 2016 Nov; 593(1):41-47. PubMed ID: 27506313
[TBL] [Abstract][Full Text] [Related]
12. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
13. The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells.
Li D; Wang H; Song H; Xu H; Zhao B; Wu C; Hu J; Wu T; Xie D; Zhao J; Shen Q; Fang L
Oncotarget; 2017 Oct; 8(49):85276-85289. PubMed ID: 29156719
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
[TBL] [Abstract][Full Text] [Related]
15. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
16. The miR-124-3p/Neuropilin-1 Axis Contributes to the Proliferation and Metastasis of Triple-Negative Breast Cancer Cells and Co-Activates the TGF-β Pathway.
Zhang J; Zhang X; Li Z; Wang Q; Shi Y; Jiang X; Sun X
Front Oncol; 2021; 11():654672. PubMed ID: 33912463
[TBL] [Abstract][Full Text] [Related]
17. MiR-27a-3p Targeting GSK3β Promotes Triple-Negative Breast Cancer Proliferation and Migration Through Wnt/β-Catenin Pathway.
Wu R; Zhao B; Ren X; Wu S; Liu M; Wang Z; Liu W
Cancer Manag Res; 2020; 12():6241-6249. PubMed ID: 32801869
[TBL] [Abstract][Full Text] [Related]
18. miR-518a-3p Suppresses Triple-Negative Breast Cancer Invasion and Migration Through Regulation of TMEM2.
Gan L; Yang H; Xiong Z; Yang Z; Wang T; Lyu G
Technol Cancer Res Treat; 2020; 19():1533033820977523. PubMed ID: 33251982
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-124-3p.1 promotes cell proliferation through Axin1-dependent Wnt signaling pathway and predicts a poor prognosis of triple-negative breast cancer.
Yang W; Cui G; Ding M; Yang M; Dai D
J Clin Lab Anal; 2020 Jul; 34(7):e23266. PubMed ID: 32125723
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
